RGENIX Presents Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104 at the 2020 AACR Annual Meeting
New York, NY - June 22, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “Correlative
RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019 at the 2020 AACR Annual Meeting
New York, NY - June 22, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-019, RGENIX’s pre-clinical antibody program in development. RGENIX’s abstract,
RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
Data from Phase 1 Trial of RGX-202 Presented at 2020 ASCO Virtual Scientific Program New York, NY - May 29, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is
RGENIX To Present RGX-202 Phase I Data at 2020 ASCO Virtual Scientific Program
New York, NY - May 21, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Dr. Johanna Bendell, Director of the Drug Development Unit at Sarah Cannon Research Center
RGENIX Presents Initial Results of Combination Trial of RGX-104 at the 2020 AACR Annual Meeting
New York, NY - April 27, 2020 - Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-104, RGENIX’s lead therapy in development. RGENIX’s abstract, “RGX-104,
Featured on In Vivo: “Rgenix: A Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis”
Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment: finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of
Rgenix Names Industry Veteran to Chief Medical Officer Role
Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry. Wasserman will oversee new Phase 1b/2 trial of lead compound RGX-104 in lung cancer patients; and RGX-202
Rgenix Presents Pre-Clinical Data on RGX-019 at the 2019 AACR Annual Meeting
Pre-clinical data demonstrates first-in-class MERTK selective inhibitor with novel mechanism of action Rgenix has initiated IND-enabling studies of RGX-019 FOR IMMEDIATE RELEASE New York, NY – April 3, 2019 – Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody